Jinzi J. Wu, PhD

Founder, Chairman, Executive Director and Chief Executive Officer

Dr.  Jinzi  Jason  WU (吴劲梓),  aged  62,  is  the  founder  of  our  Group.  Dr.  Wu  was  appointed  as  a  Director on February 25, 2014 and was appointed as the chairman of the Board on March 30, 2018. Dr. Wu was redesignated as an executive Director on April 27, 2018. Dr. Wu has served as the chief executive officer of  our  Group  since  April  2013.  Dr.  Wu  is  primarily  responsible  for  overall  management  of  the  business strategy  and  corporate  development  of  our  Group.  Dr.  Wu  is  also  involved  in  research  and  development of  all  of  the  candidates  in  the  Group’s  pipeline.  Dr.  Wu  also  holds  the  following  positions  with  other members of our Group:

• a director of PowerTree since January 2011;

• a director and chief executive officer of Ascletis BioScience since April 2013 to December 2024;

• a  director  and  chief  executive  officer  of  Ascletis  Pharmaceuticals  since  September  2014  to  January 2025;

• a director of Ascletis Pharma (China) since March 2018, an chief executive officer of Ascletis Pharma (China) since January 2023;

 • a director and chief executive officer of Ascletis Biopharma since April 2018 to January 2025;

 • a director and chief executive officer of Ascletis Xinnuo Medicine since July 2018;

 • a director of AP11 Limited since November 2018;

 • a director of SoundRidge Pharmaceuticals (Hong Kong) Co., Limited since April 2019;

 • a director and chief executive officer of Gannex Pharma Co., Ltd. since September 2019 to January 2025;

 • a manager of Gannex, LLC since October 2020; and

 • a director of ASCLETIS (AUSTRALIA) PTY LTD since October 2023.

Dr.  Wu  has  more  than  27  years  of  experience  in  pharmaceutical  research  and  development.  From February 2019 to June 2024, Dr. Wu served as a director of Sagimet, whose shares are listed on Nasdaq Stock  Market  (ticker  symbol:  SGMT).  From  June  2008  to  February  2011,  he  served  as  a  vice  president of  HIV  Drug  Discover  Performance  Unit  at  GSK  in  the  U.S.,  a  global  pharmaceutical  company  whose shares are listed on the New York Stock Exchange (ticker symbol: GSK), where he was mainly responsible for  discovery  and  development  of  multiple  pre-clinical  and  clinical  stage  drug  candidates.  From  June 2004  to  June  2008,  Dr.  Wu  served  as  a  vice  president  of  Pre-clinical  and  Basic  Research  at  Ambrilia (formerly  known  as  Procyon),  a  global  biotech  company  headquartered  in  Montreal  Canada,  whose shares were listed on the Canada Stock Exchange (ticker symbol: AMB) and were later delisted on March 4,  2011,  where  he  was  mainly  responsible  for  overseeing  research  and  development  in  areas  of  anti-viral  and  anti-cancer  drugs.  From  2002  to  2004,  Dr.  Wu  also  served  at  PhageTech  Inc.,  an  antibiotic discovery  company,  as  a  vice  president  of  research  and  development.  Dr.  Wu  also  worked  at  Immunex Corporation  as  a  group  leader  of  small  molecule  drug  discovery  in  2002  prior  to  joining  PhageTech  Inc. from 1997 to 2000, Dr. Wu served as a senior scientist at Novartis Pharmaceuticals Corporation, a global pharmaceutical  company  whose  shares  are  listed  on  New  York  Stock  Exchange  (ticker  symbol:  NVS),where he was mainly responsible for drug screening.

Dr.  Wu  received  his  bachelor’s  degree  in  physiology  from  Nanjing  University  (南京大学)  in  the  PRC  in July  1985,  his  master’s  degree  in  physiology  from  Nanjing  University  in  the  PRC  in  June  1988  and  his doctorate degree in cancer biology from University of Arizona in the U.S. in August 1996.

 

 

Judy Hejingdao Wu

Executive Director

Mrs. Judy Hejingdao WU (何净岛), aged 51, was appointed as a Director on March 30, 2018 and was re-designated as an executive Director on April 27, 2018. Mrs. Wu also served as a Director of our Company from September 9, 2015 to September 26, 2016. Mrs. Wu is the spouse of Dr. Jinzi Jason WU. Mrs. Wu has served as a vice president of our Group since January 2014 and was re-designated as a senior vice president of operations since March 1, 2021. Since joining our Group, Mrs. Wu has actively participated in  the  daily  operations  of  our  Group  and  she  is  primarily  responsible  for  overseeing  operations  of  our Group,  including  management  of  our  human  resource  and  general  affairs  of  our  Group,  among  others. Mrs. Wu also holds the following positions with other members of our Group:

• a  vice  president  of  Ascletis  BioScience,  where  she  is  mainly  responsible  for  operations  of  the

 company  since  January  2014,  a  director  of  Ascletis  BioScience  from  January  2014  to  July  2018,  a

 director and manager of Ascletis BioScience since December 2024;

• a  vice  president  of  Ascletis  Pharmaceuticals  where  she  is  mainly  responsible  for  operations  of  the

 company  from  September  2014  to  December  2021,  a  director  of  Ascletis  Pharmaceuticals  since

 January 2025;

• a manager of Gannex, LLC since January 2021;

• a director and manager of Ascletis Biopharma since January 2025; and

• a director and manager of Gannex Pharma Co., Ltd. since January 2025.

Mrs.  Wu  received  her  bachelor’s  degree  in  industrial  design  from  Zhejiang  University  (浙江大学)  in  the PRC in July 1996.

 

 

Yizhen WEI (魏以桢)

Independent Non-executive Director

Dr. Yizhen WEI (魏以桢), aged 50, was appointed as an independent non-executive Director on April 27, 2018. Dr. Wei is primarily responsible for supervising and providing independent judgement to our Board..

Dr. Wei has over 22 years of experience in clinical medicine industry. Since December 1999, Dr. Wei has served  several  positions  at  Fuwai  Hospital  –  China  Academy  of  Medical  Science  (中国医学科学院阜外医院),  including  resident  physician  from  December  1999  to  September  2003,  attending  physician  from September  2003  to  July  2009  and  consultant  physician  thereafter  and  obtained  the  professional  title  as a  chief  physician  in  July  2022.  Dr.  Wei  was  appointed  as  a  medical  appraisal  expert  of  Beijing  Medical Association  (北京市医学会)  in  December  2013.  Dr.  Wei  has  served  as  a  member  of  the  Cardiovascular Committee of the National Cardiovascular Disease Center since August 2016.

Dr.  Wei  received  his  bachelor's  degree  in  clinical  medicine  in  English  (英文医学)  from  China  Medical University  (中国医科大学)  in  the  PRC  in  July  1998  and  his  doctorate  degree  in  Surgery  from  Chinese Academy  of  Medical  Science  &  Peking  Union  Medical  College  (中国医学科学院北京协和医学院)  in  the PRC in January 2008.

 

 

Jiong GU (顾炯)

Independent Non-executive Director

Mr.  Jiong  GU (顾炯),  aged  52,  was  appointed  as  an  independent  non-executive  Director  on  April  27, 2018. Mr. Gu is primarily responsible for supervising and providing independent judgement to our Board. Mr. Gu is also the chairman of the audit committee of our Board.

 

Mr.  Gu  served  as  the  chief  financial  officer  and  vice  president  of  CMC  Holdings  Limited  (华人文化有限责任公司),  an  investment  platform  focusing  on  media  and  entertainment  investments  from  September 2016  to  July  2024.  Mr.  Gu  was  the  chief  financial  officer  of  CMC  Capital  Partners  (华人文化产业投资基金),  an  investment  fund  specializing  in  media  and  entertainment  investment  in  the  PRC  and  globally from  September  2013  to  August  2016.  From  January  2010  to  August  2013,  Mr.  Gu  served  as  the  chief financial officer in BesTV New Media Co., Ltd. (百视通新媒体股份有限公司), a PRC company principally engaged  in  the  provision  of  technical  services,  content  services  and  marketing  services  for  television terminals, computer terminals and mobile terminals through a media source platforms, whose shares are listed  on  Shanghai  Stock  Exchange  (stock  code:  600637).  From  April  2004  to  December  2009,  Mr.  Gu successively worked at UTStarcom Telecom Co., Ltd. (UT 斯达康通讯有限公司) and its holding company, UTStarcom  Inc.,  a  global  telecom  infrastructure  provider  specialized  in  the  provision  of  packet  optical transport  and  broadband  access  products  to  network  operators,  whose  shares  are  listed  on  Nasdaq (ticker  symbol:  UTSI),  where  he  was  responsible  for  accounting  and  financial  matters.  From  July  1995 to  April  2004,  Mr.  Gu  had  worked  for  Ernst  &  Young's  Shanghai  office  and  was  the  senior  manager  of the audit department when he left the firm. From June 2015 to June 2021, Mr. GU was the independent non-executive  director  of  Xinming  China  Holdings  Limited  (新明中国控股有限公司)  (HK2699).  From March  2017  to  July  2023,  he  was  the  independent  non-executive  director  of  Amlogic  (Shanghai)  Co.,Ltd  (晶晨半导体(上海)股份有限公司)  (Stock  code:  688099).  From  September  2018  to  January  2023,  he was  the  independent  non-executive  director  of  Dafa  Properties  Group  Limited  (大发地产集团有限公司) (Cancellation  of  listing  in  October  2024,  HK6111).  From  May  2019,  Mr.  Gu  has  been  appointed  as  the independent  non-executive  director  of  Mulsanne  Holding  Limited  (慕尚集团控股有限公司)  (HK1817). From December 2020, he has been appointed as the independent non-executive director of Vesync Co.,Ltd  (HK2148).  From  December  2022  to  April  2025,  he  was  the  independent  non-executive  director  of Howkingtech  International  Holding  Limited  (濠暻科技国际控股有限公司)  (HK2440).  From  April  2024,  he has been appointed as the independent non-executive director of Mao Geping Cosmetics Co., Ltd. (毛戈平化妆品股份有限公司) (HK1318). From March 2025, he has been appointed as an executive director of Shaw Brothers Holdings Limited (邵氏兄弟控股有限公司) (HK0953).

Mr. Gu has been a non-practicing member of the Chinese Institute of Certified Public Accountants since April 2004. Mr. Gu received his bachelor's degree in finance management from Fudan University (复旦大学) in the PRC in July 1995.

 

 

Ms. Lin HUA (华林)

Independent Non-executive Director

Ms. Lin HUA (华林), aged 51, was appointed as an independent non-executive Director on April 27, 2018. Ms. Hua is primarily responsible for supervising and providing independent judgement to our Board.

Since  June  2022,  Ms.  Hua  has  been  appointed  as  the  executive  director  of  Beijing  Wenguanglv  New Culture  Communication  Co.,  Ltd.*  (北京文广旅新文化传播有限公司).  Since  May  2016,  Ms.  Hua  has served as the managing director of Beijing Highgrove Cultural Communication Co., Ltd. (北京海格罗府文化传播有限公司),  a  company  primarily  conducted  cultural  communication  activities  including  organizing exhibitions and introducing and marketing foreign brands into PRC, where she was mainly responsible for overall management of its Greater China operations. From April 2010 to April 2016, Ms. Hua had worked for  Yang  Guang  Xin  Ye  Real  Property  Co.,  Ltd.  (阳光新业地产股份有限公司),  a  real  estate  development and  management  company  whose  shares  are  listed  on  the  Shenzhen  Stock  Exchange  (stock  code: 00608) and served as a vice president of commercial management department when she left. From May 2003  to  March  2010,  Ms.  Hua  worked  at  Verakin  Group  Company  Ltd.  (同景集团有限公司),  a  company primarily  conducted  real  estate  development,  education,  healthcare  and  tourism  and  served  as  board secretary  and  head  of  Beijing  headquarter  when  she  left.  From  October  2002  to  April  2003,  Ms.  Hua served  as  an  assistant  to  producer  and  program  director  at  China  Central  Television.  From  September 1996 to June 2000, Ms. Hua worked at Daiko Pacific International Advertising Inc. (大广太平洋国际广告有限公司), an international advertising company, and she served as a creative director when she left.

Ms.  Hua  received  her  bachelor's  degree  in  industrial  design  from  Zhejiang  University  (浙江大学)  in  July 1996 and her master's degree in distributed computing system from the University of Greenwich in the U.K in June 2002.

* For identification purpose only